ProPhase Labs, Inc. (PRPH): Nasdaq/NYSE listing notice — ProPhase Labs receives Nasdaq delisting notice for bid-price non-compliance; trading to suspend Jan 5

ProPhase Labs, Inc.

Nasdaq staff determination on Dec 29, 2025: company failed to regain compliance with minimum $1.00 bid price rule after two 180-day periods ending Dec 22.
Common stock trading will be suspended at the open on Jan 5, 2026; Nasdaq will file Form 25 to remove the listing.
Company intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff determination.
Concurrently, ProPhase is applying for quotation of its common stock on the OTC Markets.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ProPhase Labs, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 29, 2025, ProPhase Labs, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period, to regain compliance with the minimum bid price requirement, which expired on December 22, 2025. Nasdaq indicated that trading of the Company’s common stock will be suspended at the o

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.